The Latest From CureMatch
CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, today announced that the organization has become a proud member of CancerX. CancerX is a public-private partnership launched by The White House, which aims to be a national accelerator boosting innovation in the fight against cancer […]
CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues. CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating […]
Oncologists will be able to submit claims to payers using a Category III CPT code, paving the way for wider adoption of precision treatment options. CureMatch, Inc., a leader in precision medicine support for oncology, is pleased to announce that the American Medical Association (AMA) has issued the new Current Procedural Terminology (CPT®) Category III […]
Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in Life Science Top 50 Honoree by San Diego Business Journal. Alipour is a long-time entrepreneur in the AI space, founding multiple companies with an emphasis on the convergence of AI and the life sciences – a model now referred to […]
